Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16958452 | 0.87 | TSHR (0.46) | MAPK1MAPTALDH1A1TSHRCASP6 | |
| SCHEMBL478142 | 0.86 | MAPT (0.56) | MAPK1MAPTALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL29559211 | 0.86 | MAPT (0.56) | MAPK1MAPTALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL2722394 | 0.84 | CASP6 (0.70) | TSHRCASP6KMT2AMEN1HCAR3 | |
| SCHEMBL11690925 | 0.83 | CASP6 (0.69) | MAPK1MAPTALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL11549838 | 0.82 | ALDH1A1 (0.52) | MAPK1MAPTALDH1A1TSHRCASP6 | |
| Hydrochloric Acid SCHEMBL11549840 | 0.82 | CASP6 (0.68) | TSHRCASP6KMT2AMEN1HCAR3 | |
| SCHEMBL14656769 | 0.82 | PARP1 (0.60) | MAPTALDH1A1TSHRCASP6KMT2A | |
| SCHEMBL21544194 | 0.81 | ALDH1A1 (0.52) | MAPTALDH1A1TSHRCASP6KMT2A | |
| SCHEMBL16956692 | 0.81 | TSHR (0.41) | MAPTALDH1A1TSHRCASP6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344617-A1 | PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS. | Ivachtchenko, Alexandre Vasilievich (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9790207-B2 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790207-B2 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790207-B2 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170066746-A1 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066746-A1 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066746-A1 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017039791-A1 | PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS. | ALLA CHEM, LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017039791-A1 | PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS. | ALLA CHEM, LLC (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2015050472-A1 | FUSED INDOLE COMPOUNDS AND METHODS OF USING SAME | OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOST'YU "PANACELA LABS" (RU) | 2015-04-09 | — | — | WO | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| US-7419988-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORP (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
| US-5053509-A | Microbiocides; AIDS | LABORATOIRE ROGER BELLON (FR) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | MAPK1 786/4885MAPT 2145/4885ALDH1A1 1793/4885 |
| US-20170066746-A1 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | POLR2A, GTF3C1, SSU72 | MAPK1 111/4885MAPT 3540/4885ALDH1A1 3333/4885 |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | MAPK1 786/4885MAPT 2145/4885ALDH1A1 1793/4885 |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | MAPK1 858/4885MAPT 3569/4885ALDH1A1 863/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | MAPK1 786/4885MAPT 2145/4885ALDH1A1 1793/4885 |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | AURKA, AURKC, AURKB | MAPK1 427/4885MAPT 2850/4885ALDH1A1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.